Printer Friendly

Novel Tx for chronic sinusitis.

The U.S. Food and Drug Administration (FDA) has approved Intersect ENT's Premarket Approval (PMA) application for its Propel[TM] mometasone furoate implant, which offers localized, controlled drug delivery for patients with chronic sinusitis.

The implant, which is inserted by the physician after endoscopic sinus surgery, delivers steroid directly to the sinus tissue. The spring-like implant expands to prop open the sinus and gradually delivers an advanced corticosteroid with anti-inflammatory properties directly to the sinus lining to maintain sinus patency.

According to the company, this system has been clinically proven to prevent obstruction of the ethmoid sinus after surgery, improving postoperative outcomes and reducing the need for additional surgery and systemic steroids. The implant's safety and efficacy have been studied in three prospective clinical trials.

COPYRIGHT 2011 Vendome Group LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:treatment; Intersect ENT; PRODUCT MARKETPLACE
Comment:Novel Tx for chronic sinusitis.(treatment)(Intersect ENT)(PRODUCT MARKETPLACE)
Publication:Ear, Nose and Throat Journal
Article Type:Brief article
Geographic Code:1USA
Date:Oct 1, 2011
Previous Article:Point-of-care CT system.
Next Article:Speech, language, and voice disorders.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters